Trial Profile
Platelet Inhibition With CANgrelor and Crushed TICagrelor in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: The CANTIC Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Cangrelor (Primary)
- Indications Myocardial infarction
- Focus Pharmacodynamics
- Acronyms CANTIC
- 11 Jan 2019 Results published in the Circulation
- 13 Dec 2018 Status changed from recruiting to completed.
- 13 Dec 2017 Status changed from not yet recruiting to recruiting.